Investors
Welcome to OXB's Investors hub, your central resource for the latest company news, financial results, share information, and key updates. Here you’ll find everything you need to stay informed about our strategy, performance, and progress.
About OXB
OXB is a global contract development and manufacturing organisation (CDMO) at the forefront of cell and gene therapy. With 30 years of innovation and a deep track record in viral vector development, we partner with leading biopharma companies worldwide to accelerate the delivery of transformative medicines to patients.
As a listed company on the London Stock Exchange (LSE: OXB), we are focused on creating long-term value for our shareholders through strategic growth, operational excellence, and leadership in advanced therapies. Our mission-driven approach, combined with our scalable platform technologies and global network, positions OXB as a trusted partner and a compelling investment opportunity in one of the most dynamic areas of healthcare.
Regulatory news
Read OXB’s latest regulatory announcements, including results, trading updates, shareholder meetings, and other market disclosures – all in one place.
Results and investor materials
Access OXB’s financial results, annual reports, presentations, webcasts, and transcripts.
Corporate governance
Discover OXB’s governance framework, policies, and board committees that guide how the company creates long-term value.
Analyst coverage
The following table includes the names of sellside analysts that regularly publish research reports and recommendations on OXB.
Shareholder meetings, Circulars and Prospectuses
View major shareholders, shareholder meeting materials, including meeting notices, circulars, and prospectuses whenever you need them.
Investor events
Stay up to date with key milestones, from results announcements to capital markets days and industry events.
Investor contacts
Connect with us – find contact details for our Investor Relations team, registrars, and more.
Registrars
Company Secretary and Registered Office
Natalie Walter
Oxford Biomedica PLC
Windrush Court
Transport Way
Oxford
OX4 6LT
Tel: +44 (0) 1865 783 000
Email: cosec@oxb.com
Investor Relations
Sophia Bolhassan
Oxford Biomedica PLC
Windrush Court
Transport Way
Oxford
OX4 6LT
Tel: +44 (0) 1865 509 737
Email: ir@oxb.com
Financial and Corporate Communications
ICR Healthcare
85 Gresham Street
London
EC2V 7NQ
Tel: +44 20 3709 5700
Email: oxb@icrhealthcare.com
Website: www.icrinc.com/what-we-do/healthcare/
RBC (Joint Corporate Brokers):
Matthew Coakes
Kathryn Deegan
Tel: +44 207 653 4000
Jefferies International Limited (Joint Corporate Brokers):
Sam Barnett
Gil Bar-Nahum
Tel: +44 (0)20 7029 8000
MUFG Corporate Markets
All administrative enquiries relating to shareholdings and share dealing services should be directed to MUFG Corporate Markets in the first instance.
10th Floor
Central Square
29 Wellington Street
Leeds
LS1 4DL
Tel: +44 371 664 0391
Email: shareholderenquiries@cm.mpms.mufg.com
Website: www.signalshares.com
By logging on to www.signalshares.com you can benefit from a number of online services. You will need your investor code (IVC) which can be found on your share certificate(s) to register to use the Shareholder Portal.
Preliminary results for the year ended 31 December 2025
OXB has shared their preliminary results for FY 2025, reflecting a year of strong commercial momentum and strategic execution, driving growth and profitability.